Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1989 Aug;33(8):1313–1317. doi: 10.1128/aac.33.8.1313

beta-Lactamase stability and in vitro activity of oral cephalosporins against strains possessing well-characterized mechanisms of resistance.

C C Sanders 1
PMCID: PMC172646  PMID: 2802558

Abstract

The in vitro activity of four oral cephalosporins was assessed in dilution tests with 50 isolates of the family Enterobacteriaceae possessing well-characterized mechanisms of resistance to beta-lactam antibiotics. The interaction of the drugs with a broad array of beta-lactamases was also determined in spectrophotometric assays and tests for enzyme induction. Overall, the percentages of strains susceptible to each of the study drugs were 82% for cefixime, 62% for cefuroxime, 58% for cephalexin, and 44% for cefaclor. The poor activity of the older cephalosporins was due to a high degree of susceptibility to hydrolysis by both plasmid-mediated and chromosomally mediated beta-lactamases. For cefaclor, higher MICs were associated with higher levels of plasmid-mediated beta-lactamases in the strains. Resistance to cefuroxime was seen primarily among strains expressing high levels of class I or IV beta-lactamase. Resistance to cefixime was seen only among strains expressing high levels of class I enzymes. Neither cefixime nor cefuroxime was a strong inducer of class I beta-lactamases, although enzyme induction did appear to play a role in cefuroxime resistance in a strain of Serratia marcescens. The consistently greater activity of cefixime over cefuroxime was found not to be due to greater drug permeation into the cell. Rather, it appeared to result from the high affinity of the drug for target enzymes.

Full text

PDF
1313

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cao C., Chin N. X., Neu H. C. In-vitro activity and beta-lactamase stability of LY163892. J Antimicrob Chemother. 1988 Aug;22(2):155–165. doi: 10.1093/jac/22.2.155. [DOI] [PubMed] [Google Scholar]
  2. Chin N. X., Neu H. C. Comparative antibacterial activity of an arylglycyl oral cephalosporin, LY164846. Antimicrob Agents Chemother. 1986 Apr;29(4):703–706. doi: 10.1128/aac.29.4.703. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chin N. X., Neu H. C. In vitro activity of an oral iminomethoxy aminothiazolyl cephalosporin, R-3746. Antimicrob Agents Chemother. 1988 May;32(5):671–677. doi: 10.1128/aac.32.5.671. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cullmann W., Dick W., Stieglitz M., Opferkuch W. Comparable evaluation of orally active beta-lactam compounds in ampicillin-resistant gram-positive and gram-negative rods: role of beta-lactamases on resistance. Chemotherapy. 1988;34(3):202–215. doi: 10.1159/000238572. [DOI] [PubMed] [Google Scholar]
  5. Emmerson A. M. Cefuroxime axetil. J Antimicrob Chemother. 1988 Aug;22(2):101–104. doi: 10.1093/jac/22.2.101. [DOI] [PubMed] [Google Scholar]
  6. Fuchs P. C., Jones R. N., Barry A. L., Thornsberry C., Ayers L. W., Gavan T. L., Gerlach E. H. In vitro evaluation of cefixime (FK027, FR17027, CL284635): spectrum against recent clinical isolates, comparative antimicrobial activity, beta-lactamase stability, and preliminary susceptibility testing criteria. Diagn Microbiol Infect Dis. 1986 Jul;5(2):151–162. doi: 10.1016/0732-8893(86)90117-3. [DOI] [PubMed] [Google Scholar]
  7. Howard A. J., Dunkin K. T. Comparative in-vitro activity of a new oral carbacephem, LY163892. J Antimicrob Chemother. 1988 Oct;22(4):445–456. doi: 10.1093/jac/22.4.445. [DOI] [PubMed] [Google Scholar]
  8. Jones R. N., Barry A. L. Antimicrobial activity, spectrum, and recommendations for disk diffusion susceptibility testing of ceftibuten (7432-S; SCH 39720), a new orally administered cephalosporin. Antimicrob Agents Chemother. 1988 Oct;32(10):1576–1582. doi: 10.1128/aac.32.10.1576. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Jones R. N., Barry A. L. BMY-28100, a new oral cephalosporin: antimicrobial activity against nearly 7,000 recent clinical isolates, comparative potency with other oral agents, and activity against beta-lactamase producing isolates. Diagn Microbiol Infect Dis. 1988 Jan;9(1):11–26. doi: 10.1016/0732-8893(88)90056-9. [DOI] [PubMed] [Google Scholar]
  10. Jones R. N., Barry A. L. Beta-lactamase hydrolysis and inhibition studies of the new 1-carbacephem LY163892. Eur J Clin Microbiol. 1987 Oct;6(5):570–571. doi: 10.1007/BF02014248. [DOI] [PubMed] [Google Scholar]
  11. Jones R. N., Barry A. L. In vitro evaluations of U-76,252 (CS-807): antimicrobial spectrum, beta-lactamase stability, and enzyme inhibition. Diagn Microbiol Infect Dis. 1987 Dec;8(4):245–249. doi: 10.1016/0732-8893(87)90056-3. [DOI] [PubMed] [Google Scholar]
  12. Jorgensen J. H., Redding J. S., Howell A. W. Comparative activities of LY 164846 and other orally administered beta-lactam antibiotics against Haemophilus influenzae. Antimicrob Agents Chemother. 1986 Jun;29(6):1090–1091. doi: 10.1128/aac.29.6.1090. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kamimura T., Kojo H., Matsumoto Y., Mine Y., Goto S., Kuwahara S. In vitro and in vivo antibacterial properties of FK 027, a new orally active cephem antibiotic. Antimicrob Agents Chemother. 1984 Jan;25(1):98–104. doi: 10.1128/aac.25.1.98. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Neu H. C., Chin N. X., Labthavikul P. Comparative in vitro activity and beta-lactamase stability of FR 17027, a new orally active cephalosporin. Antimicrob Agents Chemother. 1984 Aug;26(2):174–180. doi: 10.1128/aac.26.2.174. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Neu H. C., Chin N. X., Labthavikul P. In vitro activity and beta-lactamase stability of two oral cephalosporins, ceftetrame (Ro 19-5247) and cefetamet (Ro 15-8074). Antimicrob Agents Chemother. 1986 Sep;30(3):423–428. doi: 10.1128/aac.30.3.423. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Neu H. C. In vitro activity of a new broad spectrum, beta-lactamase-stable oral cephalosporin, cefixime. Pediatr Infect Dis J. 1987 Oct;6(10):958–962. doi: 10.1097/00006454-198710000-00034. [DOI] [PubMed] [Google Scholar]
  17. O'Callaghan C. H., Sykes R. B., Griffiths A., Thornton J. E. Cefuroxime, a new cephalosporin antibiotic: activity in vitro. Antimicrob Agents Chemother. 1976 Mar;9(3):511–519. doi: 10.1128/aac.9.3.511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Obana Y., Hashizume H., Yoshimi A., Nishino T. In vitro and in vivo antibacterial activity of KY-109, a new orally active cephalosporin. J Antibiot (Tokyo) 1988 Jul;41(7):949–958. doi: 10.7164/antibiotics.41.949. [DOI] [PubMed] [Google Scholar]
  19. Okamoto S., Hamana Y., Inoue M., Mitsuhashi S. In vitro and in vivo antibacterial activities of T-2588, a new oral cephalosporin, compared with those of other oral beta-lactam antibiotics. Antimicrob Agents Chemother. 1987 Jul;31(7):1111–1116. doi: 10.1128/aac.31.7.1111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Pelosi E., Fontana R. In vitro activity and beta-lactamase stability of LY163892. Eur J Clin Microbiol Infect Dis. 1988 Aug;7(4):549–551. doi: 10.1007/BF01962613. [DOI] [PubMed] [Google Scholar]
  21. Sanders C. C., Iaconis J. P., Bodey G. P., Samonis G. Resistance to ticarcillin-potassium clavulanate among clinical isolates of the family Enterobacteriaceae: role of PSE-1 beta-lactamase and high levels of TEM-1 and SHV-1 and problems with false susceptibility in disk diffusion tests. Antimicrob Agents Chemother. 1988 Sep;32(9):1365–1369. doi: 10.1128/aac.32.9.1365. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Sanders C. C., Sanders W. E., Jr, Goering R. V., Werner V. Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes. Antimicrob Agents Chemother. 1984 Dec;26(6):797–801. doi: 10.1128/aac.26.6.797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Sanders C. C., Sanders W. E., Jr, Moland E. S. Characterization of beta-lactamases in situ on polyacrylamide gels. Antimicrob Agents Chemother. 1986 Dec;30(6):951–952. doi: 10.1128/aac.30.6.951. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Sanders C. C., Sanders W. E., Jr Type I beta-lactamases of gram-negative bacteria: interactions with beta-lactam antibiotics. J Infect Dis. 1986 Nov;154(5):792–800. doi: 10.1093/infdis/154.5.792. [DOI] [PubMed] [Google Scholar]
  25. Shigi Y., Matsumoto Y., Kaizu M., Fujishita Y., Kojo H. Mechanism of action of the new orally active cephalosporin FK027. J Antibiot (Tokyo) 1984 Jul;37(7):790–796. doi: 10.7164/antibiotics.37.790. [DOI] [PubMed] [Google Scholar]
  26. Tamura A., Okamoto R., Yoshida T., Yamamoto H., Kondo S., Inoue M., Mitsuhashi S. In vitro and in vivo antibacterial activities of ME1207, a new oral cephalosporin. Antimicrob Agents Chemother. 1988 Sep;32(9):1421–1426. doi: 10.1128/aac.32.9.1421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Tomatsu K., Ando S., Masuyoshi S., Kondo S., Hirano M., Miyaki T., Kawaguchi H. In vitro and in vivo evaluations of BMY-28100, a new oral cephalosporin. J Antibiot (Tokyo) 1987 Aug;40(8):1175–1183. doi: 10.7164/antibiotics.40.1175. [DOI] [PubMed] [Google Scholar]
  28. Utsui Y., Inoue M., Mitsuhashi S. In vitro and in vivo antibacterial activities of CS-807, a new oral cephalosporin. Antimicrob Agents Chemother. 1987 Jul;31(7):1085–1092. doi: 10.1128/aac.31.7.1085. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Yamanaka H., Chiba T., Kawabata K., Takasugi H., Masugi T., Takaya T. Studies on beta-lactam antibiotics. IX. Synthesis and biological activity of a new orally active cephalosporin, cefixime (FK027). J Antibiot (Tokyo) 1985 Dec;38(12):1738–1751. doi: 10.7164/antibiotics.38.1738. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES